P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
P905:KARMMA 3 试验(3 期随机对照试验)中接受过三类药物治疗的复发/难治性多发性骨髓瘤 (TCE RRMM) 患者的患者报告结局:IDECABTAGENE VICLEUCEL (IDE-CEL) 与标准方案的比较
期刊:Yonsei Medical Journal
影响因子:2.8
doi:10.3349/ymj.2014.55.4.1063
Choi, Il; Hyun, Seung-Jae; Kang, Joong-Koo; Rhim, Seung-Chul; Delforge, Michel; Patel, Krina; Eliason, Laurie; Dhanda, Devender; Shi, Ling; Guo, Shien; Marshall, Thomas; Arnulf, Bertrand; Cavo, Michele; Nooka, Ajay; Manier, Salomon; Callander, Natalie; Giralt, Sergio; Einsele, Hermann; Ailawadhi, Sikander; Popa Mckiver, Mihaela; Cook, Mark; Rodríguez-Otero, Paula